TMPRSS2-ERG fusion heterogeneity in Multifocal prostate cancer: Clinical and biologic implications
TMPRSS2-ERG fusion heterogeneity in Multifocal prostate cancer: Clinical and biologic implications
复制标题
DOI：
10.1016/j.urology.2007.08.032
复制
发表时间：
2007-10-01
期刊：
影响因子：
2.1
通讯作者：
Rubin, Mark A.
中科院分区：
文献类型：
--
作者：
Barry, Marc;Perner, Sven;Rubin, Mark A.
目的探讨多灶性前列腺癌中TMPRSS2-ERG融合的克隆特征。方法从80例连续根治性前列腺切除术标本中，鉴定出32例空间分离的多发肿瘤。在每种情况下，我们使用ERG裂解间期荧光原位杂交法评估了两到三个肿瘤灶TMPRSS2-ERG融合。结果单个肿瘤灶表现出融合状态的同质性（病灶内克隆同质性）。在32例病例中，有19例（59%）病例内的所有灶具有相同的融合状态（灶间均匀性）。19例中15例（80%）无病灶融合，4例（20%）病灶均融合。在32例病例中，13例（41%）在一个病例内表现出融合状态的异质性（局灶间克隆异质性）。结论：在本研究中，我们证实了TMPRSS2-ERG融合在前列腺癌多发肿瘤中的局间异质性和局内同质性。这些发现支持前列腺癌的多克隆性，对针活检策略和基于尿液的筛查试验的发展具有临床意义。
OBJECTIVES To characterize the clonality of TMPRSS2-ERG fusion in multifocal prostate cancer.METHODS From 80 consecutive radical prostatectomy specimens, we identified 32 cases with multiple spatially separate tumors. In each case, we assessed two to three tumor foci for TMPRSS2-ERG fusion using an ERG break-apart interphase fluorescence in situ hybridization assay.RESULTS Individual tumor foci showed homogenity for fusion status (intrafocal clonal homogenity). In 19 (59%) of the 32 cases, all foci within a case had the same fusion status (interfocal homogeneity). In 15 (80%) of the 19 cases, no foci had fusion, and in 4 (20%), all foci had fusion. Of the 32 cased, 13 (41%) demonstrated heterogeneity for fusion status within a case (interfocal clonal heterogeneity).CONCLUSIONS In this study, we have demonstrated interfocal heterogeneity and intrafocal homogeneity for TMPRSS2-ERG fusion in prostate cancer with multiple tumors. These findings support the multiclonal nature of prostate cancer with clinical implications for needle biopsy strategies and the development of urine-based screening tests.